AstraZeneca Gets Crowded by Merck, Bristol on Lung Cancer

Updated on
  • CEO says competing products cleared `far faster' than expected
  • Lung cancer drug to be submitted in first half of next year

AstraZeneca Plc may shelve a plan for seeking accelerated approval of a key experimental cancer drug because Bristol-Myers Squibb Co. and Merck & Co. moved faster to crowd the U.S. market for lung tumors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.